NCT05227456

Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Saskatchewan Health Authority - Regina Area · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to assess the efficacy of an implantable etonogestrel device in reducing hysterectomy rate in patients with a failed endometrial ablation.

Detailed description

The researchers aim to determine whether use of etonogestrel implant in patients with failed endometrial ablation significantly decreases hysterectomy rate. Changes in pelvic pain and vaginal bleeding will be assessed. Time to hysterectomy will be examined. The researchers hypothesize that treatment of failed endometrial ablation with etonogestrel implant will decrease pelvic pain and vaginal bleeding resulting in a significantly decreased need for hysterectomy.

Conditions

• Abnormal Uterine Bleeding
• Dysmenorrhea

Interventions

Type	Name	Description
DRUG	Etonogestrel 68mg implant	Implant will be inserted
DEVICE	Etonogestrel 68mg implant	Implant will be inserted

Timeline

• Start date: 2022-07-01
• Primary completion: 2024-04-30
• Completion: 2024-04-30
• First posted: 2022-02-07
• Last updated: 2025-11-25

Locations

1 site across 1 country: Canada

Regulatory

• FDA-regulated drug study
• FDA-regulated device study